DiaCarta Clinical Services Laboratory Receives CLIA Certification
DiaCarta Inc. today announced that DiaCarta Clinical Services Laboratory (DCSL) successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The State of California inspector gave DCSL permission to begin offering QClamp-based molecular diagnostic patient and clinical trial testing services.
The DiaCarta-owned and -operated laboratories, both in Richmond, California, and Nanjing, China, enable clinical and research laboratories, as well as diagnostic and pharmaceutical companies, to incorporate complex molecular tests into clinical practice. The CLIA certification ensures that all of its processes are standardized to consistently meet federal and Clinical Laboratory Standards Institute (CLSI) guidelines for accuracy, precision, sensitivity, calibration and control. In addition, all of the DCSL assays have been validated for clinical applications to ensure reproducible results.
Located in Richmond, California, DCSL is a facility of over 16,000 square feet. The laboratory specializes in patient testing and clinical trial services for gene mutation and gene expression monitoring, genotyping and copy number analysis, as well as other molecular diagnostic tests. The company is dedicated to the science of rapid, highly sensitive detection technologies and diagnostic solutions for healthcare that positively impact treatment plans and improve the wellbeing of individuals around the world. QClamp®, a revolutionary new way to screen for somatic mutations in cancer genes, utilizes a sequence-specific xeno-nucleic acid (XNA) clamp that suppresses PCR amplification on wild-type DNA template and allows selective amplification of only mutant template. With its detection sensitivity below 0.1%, QClamp® is ideal for a variety of samples including FFPE tissue, liquid biopsy and traditionally challenging cytology specimens. QClamp® on next-generation sequencing (NGS), the OptiSeq™ platform, can implement mutant DNA target enrichment to detect very low copy mutant numbers that are not possible by conventional NGS protocols.
“We are very excited about the new addition of CLIA-certified clinical laboratory testing to our suite of product offerings. Our CLIA certification is an important regulatory milestone and demonstrates our commitment to quality laboratory testing to provide accurate, reliable and timely test results,” said Dr. Aiguo Zhang, Founder and CEO of DiaCarta. “With our Independent Clinical Service Lab also in Nanjing, China, we are well positioned to become a key companion diagnostic partner with pharmaceutical companies for global clinical trials of novel targeted therapies.”
About DiaCarta Inc.
DiaCarta is a translational genomics and personalized diagnostics company headquartered in Richmond, California with business and clinical operations in Shanghai and Nanjing, China, respectively. We are dedicated to the science of rapid and highly sensitive detection technologies and diagnostic solutions for healthcare that positively impact treatment plans and improve the well-being of individuals around the world. QClamp®, a revolutionary new way to screen for tumor oncogenic driver and resistance mutations in tumor DNA derived from cancer patients, utilizes a sequence-specific xeno-nucleic acid (XNA) clamp that suppresses PCR amplification on wild-type DNA template and allows selective amplification of only mutant template with detection sensitivity below 0.1% for a variety of samples including FFPE tissue, liquid biopsy and traditionally challenging cytology specimens. The QClamp® XNA-PCR technology has also been applied for mutant DNA target enrichment on our OptiSeq™ next-generation sequencing platform. QuantiVirus™ HPV cervical cancer and DigiPlex™ genotyping tests are the products powered by SuperbDNA™ and multiplex bar-coding technology platforms, respectively. To learn more, visit https://www.diacarta.com.
DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test, designed for tumor response monitoring, is now eligible for reimbursement from Medicare, effective January 1, 2024.
DiaCarta announced today that DiaCarta received US FDA 510(k) clearance for it’s over the counter (OTC) at home iColon Fecal Occult Blood Test (FOBT) that enables early detection of blood in stool at home, which is clinically relevant in gastrointestinal disorders and colorectal cancer.
DiaCarta and HMC/HML Team up for Customizing Lab Development Test Validations and Compliances in the US Market
DiaCarta announced that the company has formed strategic partnership with Hopkins MedTech Compliance and Hopkins MedTech Lab Services.
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced the termination of its Business Combination Agreement with HH&L Acquisition Co.
DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta’s leadership and commitment to excellence.